![Lynn Seely](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lynn Seely
Chief Executive Officer at
LYELL IMMUNOPHARMA, INC.
Net worth: 1 M $ as of 2026-05-30
Profile
Lynn Seely is President & Chief Executive Officer at Lyell Immunopharma, Inc. since 2026.
Former roles include Chief Executive Officer at Myovant Sciences, Inc. from 2019 to 2020; President, Chief Executive Officer & Director at Myovant Sciences Ltd. from 2016 to 2021; Associate Director-Clinical Development at Chiron Corp.
from 1996 to 2000; Lead Independent Director at Blueprint Medicines Corp.
from 2016 to 2025; Director at Roivant Sciences GmbH; Chief Medical Officer at Orion Acquisition Corp.
II in 2005; Vice President-Clinical Development at Anesiva, Inc. from 2002 to 2005; Vice President-Clinical Development at Pro-Duct Health, Inc. from 2000 to 2001; Faculty Member at the University of California San Diego from 1992 to 1996; Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015; Vice President-Clinical Development at Cytyc Health Corp.
from 2001 to 2002; Vice President-Clinical Development at Corgentech, Inc. in 2005; Chief Resident-Internal Medicine at Yale School of Medicine.
Education includes an undergraduate degree from the University of Oklahoma in 1981 and a doctorate from the University of Oklahoma College of Medicine in 1985.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-10 | 73,878 ( 0.32% ) | 1 M $ | 2026-05-30 |
Lynn Seely active positions
| Companies | Position | Start |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Executive Officer | 2022-12-14 |
Former positions of Lynn Seely
| Companies | Position | End |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 2025-07-16 |
| MYOVANT SCIENCES LTD. | Chief Executive Officer | 2020-12-31 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Chief Executive Officer | 2020-01-03 |
| MEDIVATION INC | Chief Tech/Sci/R&D Officer | 2015-10-14 |
Orion Acquisition Corp. II
 Orion Acquisition Corp. II Financial ConglomeratesFinance Development stage company | Chief Tech/Sci/R&D Officer | 2005-06-28 |
Training of Lynn Seely
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
77
1st degree connections
16
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Orion Acquisition Corp. II
Orion Acquisition Corp. II Financial ConglomeratesFinance Development stage company | Finance |
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for pain management | Health Technology |
Pro-Duct Health, Inc.
 Pro-Duct Health, Inc. Medical SpecialtiesHealth Technology Develops medical products for the evaluation of breast cancer | Health Technology |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oklahoma
 University of Oklahoma Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Engages in the development of novel small molecule drugs to treat serious diseases | Health Technology |
Cytyc Health Corp. | |
Corgentech, Inc.
 Corgentech, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
University of Oklahoma College of Medicine
 University of Oklahoma College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
- Stock Market
- Insiders
- Lynn Seely
